PharmiWeb.com - Global Pharma News & Resources

Marketing - Press Releases

Date Title Company
05-May-2020 Independent expert review of data supports the potential of XF-73 to address antimicrobial resistance Destiny Pharma
05-May-2020 Vifor Pharma announces Akebia’s Positive top-line results from global phase-III program of vadadustat for treatment of anaemia due to Chronic Kidney Disease in adult dialysis-dependent patients Vifor Pharma
01-May-2020 Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages 6 Months and 18 Years With the R117H Mutation in the CFTR Gene Vertex Pharmaceuticals
30-Apr-2020 New dates announced for Smart Water Systems 2020 SMi Group Ltd
29-Apr-2020 BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany BioNTech SE
29-Apr-2020 SANGAMO THERAPEUTICS ANNOUNCES PRESENTATIONS AT 2020 ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY SANGAMO THERAPEUTICS
29-Apr-2020 Audited results for the year ended 31 December 2019 and clinical development update Destiny Pharma plc
29-Apr-2020 Bone Therapeutics secures EUR 11.0 million financing Bone Therapeutics
29-Apr-2020 Polyplus' growth investment expands partnership with Warburg Pincus and ArchiMed Polyplus-transfection
29-Apr-2020 Let local clinicians and managers lead the redesign of services NHS England
29-Apr-2020 Richmond Research Institute partnering to ensure faster COVID-19 point of care testing and longer-term immunity studies Richmond Research Institute
28-Apr-2020 Medical Realities launches a free digital online resource to train 1m healthcare workers for COVID-19 Medical Realities
28-Apr-2020 NICE RECOMMENDS STELARA® (USTEKINUMAB) FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS The Janssen Pharmaceutical Companies of Johnson & Johnson
28-Apr-2020 New dates announced for Smart Water Systems 2020 SMi Group
28-Apr-2020 NICE RECOMMENDS STELARA® (USTEKINUMAB) FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS Janssen
27-Apr-2020 Top-Level industry professionals to speak at Pain Therapeutics Conference in 2 weeks SMi Group
27-Apr-2020 Orgenesis completes acquisition of Tamir Biotechnology, Inc. assets including broad spectrum antiviral platform Orgenesis
27-Apr-2020 Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival Sanofi
27-Apr-2020 Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients Sanofi
27-Apr-2020 Valo Therapeutics to Support Development of a Pan – Coronavirus Vaccine Valo Therapeutics